WithdrawnPhase 2NCT00489710

Talabostat in Treating Patients With Metastatic Kidney Cancer

Studying Acquired cystic disease-associated renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Nebraska
Principal Investigator
Ralph Hauke, MD
University of Nebraska
Intervention
talabostat mesylate(drug)
Eligibility
19-120 years · All sexes
Timeline
20062007

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00489710 on ClinicalTrials.gov

Other trials for Acquired cystic disease-associated renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Acquired cystic disease-associated renal cell carcinoma

← Back to all trials